Investing

Madrigal Pharmaceuticals : MDGL

MDGL

Stock Data

$510.04

$0.32 (0.06%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Madrigal Pharmaceuticals Inc is a biopharmaceutical company in the clinical stage, primarily focused on creating treatments for non-alcoholic steatohepatitis (NASH), a liver disease. Their main product in development is resmetirom, aimed at treating NASH through a novel approach as a liver-directed thyroid hormone receptor beta agonist. Currently, resmetirom is undergoing Phase 3 clinical trials. The company operates out of West Conshohocken, Pennsylvania.

Latest Activity

MDGLMadrigal Pharmaceuticals

Q2 2026

Jul 30, 7:03am ET

EPS

-$1.99

est -$2.23+10.8%

Revenue

$364M

est $353M+3.3%

Madrigal's MASH therapy Rezdiffra just crossed 50,000 patients as Q2 revenue surged 71% year-over-year, beating estimates by 3.3% on the back of accelerating physician adoption and a direct-to-consumer push that's turning a once-obscure liver disease into a scaled commercial opportunity.

ShareRead more

All Madrigal Pharmaceuticals Articles

10 Articles

Lee Jackson | Aug 4, 2026 at 8:11 AM EDT

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More

Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the…

Joel South | May 3, 2026 at 9:30 AM EDT

3 Biotech Stocks to Watch for Respectable Growth Beyond AI

Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small…

Trey Thoelcke | Jan 31, 2026 at 8:15 AM EST

Insiders Are Still Scooping Up Under Armour and WR Berkley Shares

Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares…

Trey Thoelcke | Aug 28, 2025 at 8:45 AM EDT

Biopharma and Energy Execs Lead Weekly Insider Buying

The past week's most notable insider buying included a biopharmaceutical company, a pipeline company, and an industrial products maker.

Trey Thoelcke | Feb 5, 2025 at 8:45 AM EST

Prediction: This Pharma Stock Will Be the Best Performer in 2025

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big…

Chris MacDonald | Oct 5, 2024 at 6:18 AM EDT

Is John Paulson’s Best Investment Ever a Buy or Sell

John Paulson is among the most well-known billionaires, famous for his long-term investing returns via his hedge fund Paulson &…

Rich Duprey | Oct 3, 2024 at 7:53 PM EDT

Is John Paulson’s Best Investment Ever a Buy or Sell

The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the…

Trey Thoelcke | Dec 16, 2023 at 9:49 AM EST

Huge Warren Buffett Purchase Highlights Hot Insider Buying

Warren Buffett's Berkshire Hathaway has bolstered its stake in Occidental Petroleum with a huge purchase of shares. Insider buying is…

Trey Thoelcke | Dec 7, 2023 at 11:50 AM EST

See Which Inside Buyers Are Scooping Up More Shares Now

Some of the biggest insider buying since the Thanksgiving holiday has come from repeat buyers, including Bill Ackman, who continues…

Trey Thoelcke | Dec 1, 2023 at 10:50 AM EST

Insiders Are Loading Up on These Biotech and Energy Stocks

Notable insider buying in the past week included biotech and energy companies, including some that have just gone public. Also,…